Becton Dickinson and Co. (BDX) Shares Sold by Johnston Asset Management LLC
Johnston Asset Management LLC reduced its position in shares of Becton Dickinson and Co. (NYSE:BDX) by 1.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 93,429 shares of the company’s stock after selling 940 shares during the period. Johnston Asset Management LLC’s holdings in Becton Dickinson and were worth $15,845,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. Bank of Montreal Can purchased a new stake in shares of Becton Dickinson and during the second quarter worth $118,746,000. UBS Group AG increased its stake in shares of Becton Dickinson and by 52.8% in the first quarter. UBS Group AG now owns 1,345,361 shares of the company’s stock worth $204,253,000 after buying an additional 464,650 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Becton Dickinson and by 20.4% in the first quarter. JPMorgan Chase & Co. now owns 2,300,833 shares of the company’s stock worth $349,312,000 after buying an additional 389,262 shares during the period. BlackRock Fund Advisors increased its stake in shares of Becton Dickinson and by 9.5% in the first quarter. BlackRock Fund Advisors now owns 3,911,925 shares of the company’s stock worth $593,908,000 after buying an additional 340,497 shares during the period. Finally, Findlay Park Partners LLP increased its stake in shares of Becton Dickinson and by 22.6% in the first quarter. Findlay Park Partners LLP now owns 1,537,058 shares of the company’s stock worth $233,356,000 after buying an additional 282,995 shares during the period. Institutional investors and hedge funds own 81.96% of the company’s stock.
Shares of Becton Dickinson and Co. (NYSE:BDX) traded down 0.73% during mid-day trading on Monday, hitting $178.41. The stock had a trading volume of 720,467 shares. Becton Dickinson and Co. has a 12-month low of $129.50 and a 12-month high of $181.76. The stock has a market cap of $37.99 billion, a price-to-earnings ratio of 34.05 and a beta of 0.93. The firm’s 50-day moving average price is $175.87 and its 200 day moving average price is $167.90.
Becton Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 4th. The company reported $2.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.21 by $0.14. The business earned $3.20 billion during the quarter, compared to the consensus estimate of $3.21 billion. Becton Dickinson and had a return on equity of 24.26% and a net margin of 9.24%. Becton Dickinson and’s revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the company earned $2.05 EPS. Equities analysts forecast that Becton Dickinson and Co. will post $8.56 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 30th. Investors of record on Friday, September 9th were given a dividend of $0.66 per share. The ex-dividend date of this dividend was Wednesday, September 7th. This represents a $2.64 annualized dividend and a dividend yield of 1.48%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 50.19%.
A number of equities research analysts have recently weighed in on BDX shares. Citigroup Inc. downgraded Becton Dickinson and from a “neutral” rating to a “sell” rating and lowered their price target for the company from $167.00 to $165.00 in a report on Friday, September 23rd. Bank of America Corp. restated a “buy” rating on shares of Becton Dickinson and in a research note on Tuesday, July 12th. Cowen and Company restated an “outperform” rating and set a $185.00 price objective on shares of Becton Dickinson and in a research note on Tuesday, August 16th. Jefferies Group restated a “buy” rating on shares of Becton Dickinson and in a research note on Friday, August 5th. Finally, Leerink Swann restated a “hold” rating on shares of Becton Dickinson and in a research note on Tuesday, August 9th. One analyst has rated the stock with a sell rating, seven have given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $170.82.
In related news, insider Gary M. Cohen sold 29,367 shares of the firm’s stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $176.81, for a total transaction of $5,192,379.27. Following the completion of the transaction, the insider now owns 125,870 shares in the company, valued at approximately $22,255,074.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Linda M. Tharby sold 11,704 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $177.27, for a total value of $2,074,768.08. Following the transaction, the insider now owns 22,146 shares of the company’s stock, valued at approximately $3,925,821.42. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Receive News & Stock Ratings for Becton Dickinson and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co. and related stocks with our FREE daily email newsletter.